Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new treatment combination for adults with advanced small cell lung cancer SCLC. The study compares a medicine called obrixtamig combined with standard treatment atezolizumab, carboplatin, and etoposide against the standard treatment alone. Obrixtamig is an antibody-like molecule designed to help the immune system fight cancer. The study also tests a new medical device to measure levels of a tumor marker called DLL3. Participants are randomly assigned to one of two groups. One group receives obrixtamig plus the standard treatment, while the other group receives only the standard treatment. All drugs are given through infusions into a vein. Participants in the obrixtamig group stay overnight at the study site after their first two obrixtamig treatments. The study lasts for up to three years, during which participants visit the study site regularly. Throughout the study, doctors monitor tumor size to compare results between groups. They also check participants overall health and note any side effects. Researchers measure outcomes such as overall survival, progression-free survival, symptom changes, treatment responses, and any treatment-related side effects. Participants are closely observed for up to 36 months to evaluate these effects and safety.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are investigating a multi-sub-study clinical trial called the Beat AML Master Protocol, focused on biomarker-based treatment for acute myeloid leukemia AML. This Phase 1b23 trial aims to develop a genomic screening method to assign patients to various sub-studies based on the specific AML subtype or other myeloid malignancies. The goal is to evaluate different investigational therapies or combinations to advance targeted treatments for approval. Participants may receive different treatments depending on their assigned sub-study, including investigational drugs like SNDX-5613, venetoclax combined with azacitidine, ZE46-0134, ficlatuzumab, samalizumab, BI 836858, AG-221, entospletinib, pevonedistat, AZD5153, gilteritinib, and others. Treatment schedules vary widely, with dosing cycles ranging from continuous daily oral medications to intravenous infusions on specific days within 28-day cycles. Some studies include dose escalation followed by expansion phases, and treatment may continue until disease progression, unacceptable toxicity, or other protocol-defined criteria. Participants will undergo genomic and biomarker testing to guide treatment assignment within the protocol. They will have regular visits for treatment administration, safety monitoring, disease response evaluation, and laboratory assessments. Outcome measures include the proportion of patients completing biomarker studies within 7 days, assignment to targeted therapies, clinical response rates, event-free survival, overall survival, and quality of life assessments, with follow-up extending up to several years. The trial involves complex monitoring of safety and efficacy to better understand and improve AML treatment options.
Actively Recruiting
Researchers are evaluating treatments for participants with metastatic colorectal cancer who have a specific KRAS p.G12C mutation and have not received prior treatment. The study compares progression-free survival between two groups one receiving sotorasib, panitumumab, and FOLFIRI, and the other receiving FOLFIRI with or without bevacizumab-awwb. This is a phase 3 randomized trial aiming to understand which combination better manages the disease. Participants in one group take sotorasib daily as an oral tablet while receiving panitumumab and FOLFIRI every two weeks through intravenous infusions. The other group receives FOLFIRI every two weeks, with or without bevacizumab-awwb, also given by intravenous infusion every two weeks. The study treatments continue according to these schedules to compare their effects. Throughout the trial, participants will undergo assessments to measure progression-free survival using RECIST v1.1 criteria for up to approximately three years. Additional outcomes like overall survival, response rates, duration of response, and safety events are monitored for up to five years. Researchers will collect blood samples to measure sotorasib levels during early treatment cycles. Participants are closely observed through scheduled visits and tests to evaluate treatment effects and safety over the study duration.